<html><head><title>Jain Foundation Inc | Research Database | Dysferlin interacting proteins | Affixin</title><meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"><link rel="stylesheet" href="../style-old.css" type="text/css" /></head><body leftmargin="0" topmargin="10" marginwidth="0" marginheight="10"><? include 'includes/main.php'; ?>            <td valign="top" align="center"><table width="92%" border="0" cellspacing="0" cellpadding="0">              <tr>                <td valign="top" height="13"></td>              </tr>              <tr>                <td><p class="section style3">Research Database</p>				<p><a href="database_dysferlin interactors.php">&lt;&lt;Back</a></p>                      <p><strong>Affixin</strong></p>                      <strong>1. What is Affixin?</strong>					  <p>Affixin (beta-parvin) is a focal adhesion protein that is ubiquitously expressed, with highest expression in heart and skeletal muscles.					  <br><em>Yamaji et al., JCB 153 (6): 1251-1264</em></br></p>					  <strong>2. How was the interaction between Affixin and Dysferlin demonstrated?</strong>					  <p>Affixin was shown to interact with dysferlin in mouse and human skeletal muscles by coimmunoprecipitation. The C-terminal intracellular region of Dysferlin was identified as the Affixin binding domain and the CH1 domain of Affixin was identified as Dysferlin-interacting region.					  <em><br>Matsuda et al., J Neuropathol Exp Neurol 64 (4): 334- 340</em> 				      <p><strong>3. Have knock-out mice been generated for Affixin? If yes, what is their phenotype?</strong></p>					  <p>Affixin knockout mice have not yet been described.</p>					  <p><strong>4. Are there any naturally occurring Affixin mutations and/or deficiencies know to be associated with human disorders?					  </strong></p>                      <p>No human disorders have been attributed to Affixin deficiency as of yet.</p>					  <p><strong>5.	How are the levels of Affixin secondarily affected in case of Dysferlin-deficiency?</strong></p>					  Deficiency of Dysferlin in MM and LGMD2B causes secondary reduction of Affixin at the sarcolemma. 					  <br><em>Matsuda et al., J Neuropathol Exp Neurol 64 (4): 334- 340</em></br>                  </p></td>              </tr>              <tr>                <td>&nbsp;</td>              </tr>            </table></td>          </tr>          <tr>            <td bgcolor="#FDFFC6" align="center" valign="top">&nbsp;</td>            <td bgcolor="ffffff">&nbsp;</td>          </tr>          <tr>            <td height="30" align="right" bgcolor="#FDFFC6"></td>            <td height="30" align="right" valign="middle" bgcolor="#FDFFC6"><p class="footer">                <? include 'includes/footer.php'; ?>              </p>            </td>          </tr>        </table></td>        <td background="../images/bg_dot.gif" width="1"></td>      </tr>    </table>    <table width="780" border="0" cellspacing="0" cellpadding="0">      <tr>        <td height="4" background="../images/bg_green.gif"></td>      </tr>    </table>		</td>  </tr></table></body></html>